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Osteoarthritis (OA), the most prevalent form of arthritis in the elderly, is characterized by the degradation of articular cartilage and has
a strong genetic component. Our aim was to identify genetic variants involved in risk of knee OA in women. A pooled genome-wide
association scan with the Illumina550 Duo array was performed in 255 controls and 387 cases. Twenty-eight variants with p < 1 3
105 were estimated to have probabilities of being false positives %0.5 and were genotyped individually in the original samples and
in replication cohorts from the UK and the U.S. (599 and 272 cases, 1530 and 258 controls, respectively). The top seven associations
were subsequently tested in samples from the Netherlands (306 cases and 584 controls). rs4140564 on chromosome 1 mapping 50 to
both the PTGS2 and PLA2G4A genes was associated with risk of knee OA in all the cohorts studied (overall odds ratio ORMH ¼ 1.55
95% C.I. 1.30–1.85, p < 6.9 3 107). Differential allelic expression analysis of PTGS2 with mRNA extracted from the cartilage of
joint-replacement surgery OA patients revealed a signiﬁcant difference in allelic expression (p < 1.0 3 106). These results suggest
the existence of cis-acting regulatory polymorphisms that are in, or near to, PTGS2 and in modest linkage disequilibrium with
rs4140564. Our results and previous studies on the role of the cyclooxygenase 2 enzyme encoded by PTGS2 underscore the importance
of this signaling pathway in the pathogenesis of knee OA.Introduction
Osteoarthritis (OA [MIM 165720]) of the knee is a common
complex disorder resulting in joint disability with known
constitutional and environmental risk factors for develop-
ment and progression, such as age, obesity, hormonal
status, bone density, physical activity, and past history of
trauma.1 Knee OA also has an important genetic compo-
nent, and several studies have investigated the role of can-
didate genes in the risk of hip and knee OA. Several genes
with common polymorphisms consistently affecting risk
of OA have been reported to date (e.g., 2–6). In general,
the genetic variants involved do not have large attributable
risks. Rather, in common with other complex traits, the
increased risks for carrying a predisposing genetic variant
appear to be fairly modest, with most of them having
odds ratios between 1.3 and 2.0, suggesting that a large
number of genes each with relatively modest effect are
contributing to the genetic etiology of OA.7
To date, two large case-control association scans have
been reported. Mototani and coworkers8 tested 72,000
markers for association with hip OA, and identiﬁed a vari-
ant in the calmodulin 1 (CALM1 [MIM 114180]) gene to be
strongly associated in the Japanese population. However,The Amstudies in UK samples failed to show an association of
this variant with hip9 or knee OA.3 Spector and co-
workers10 examined 25,000 genic SNPs for association
with radiographic knee osteoarthritis in men and women
from the UK and identiﬁed a SNP in a gene of unknown
function (the leucine-rich repeats and calponin homology
domain-containing 1, LRCH1 [MIM 610368]). That genetic
variant has failed to show an association in subsequent
studies in both Asian and European samples.11,12 To our
knowledge, to date no large-scale genome-wide associa-
tion scan with extensive coverage (i.e., 100,000 or more
markers) of knee OA has been carried out.
In this study, we report a large-coverage pooled genome-
wide association scan (GWAS) of knee OA and the results of
successively testing individually the most highly associ-
ated SNPs in ﬁve case-control studies.
Material and Methods
Study Subjects
We combined data from ﬁve independent cohorts into a discovery
sample, a UK replication cohort, a U.S. replication cohort, and
a Dutch replication cohort (see Figure 1). The numbers of cases
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replication samples is shown in Table 1. All study subjects were of
self-reported white ethnicity.
Deﬁnitions of OA
All affected individuals taking part in this study had standardized
extended weight bearing anteroposterior radiographs of their
Figure 1. Study Strategy Used for Discovery and Replication1232 The American Journal of Human Genetics 82, 1231–1240, Juneknees. Two different deﬁnitions of OA were used, clinical OA for
the UK and US case controls and radiographic OA for the
TwinsUK, Chingford, and Rotterdam population-based studies
(Table 1).
Clinical OA was deﬁned by American College of Rheumatology
criteria,13 namely, patients had knee pain due to OA on most days
during at least 1 month in a 3 month period prior to screening,
with the addition of at least one of the following: age >50 years,
morning knee stiffness lasting >30 min, or knee crepitus.
For radiographic OA, the description of scoring of the radio-
graphs is described elsewhere in detail.14,15 Radiographs were
scored for the presence of radiographic OA (ROA) of the knee
according to the Kellgren/Lawrence (K/L) score.16 Knee OA was
deﬁned as a K/L scoreR2 of one or both joints.
The number of patients and controls from each cohort taking
part in the discovery and replication studies, the diagnosis criteria,
and their descriptive characteristics are shown in Table 1. Speciﬁc
characteristics of each cohort are summarized below.
UK Case-Control Study
Women affected by knee OA cases were recruited in Nottingham
both from families with a history of OA and from clinic popula-
tions. All research participants gave written informed consent to
take part. The study protocol was approved by the Leicestershire,
Northamptonshire and Rutland Research Ethics Committee.
U.S. Case-Control Study
Female knee OA patients attending clinics in the mid-Atlantic re-
gion of the U.S. (Maryland and North Carolina) provided written
informed consent before entering the study, which was conducted
in accordance with International Conference on Harmonization
of Technical Requirements for Registration of Pharmaceuticals
for Human Use Guidelines for Good Clinical Practice and was
administered by the institutional review boards. Controls were
U.S. white women over the age of 50 not diagnosed for OA.
The Rotterdam Study
The Rotterdam study is a prospective, population-based cohort in-
vestigating determinants, incidence, and progression of chronic
disabling diseases in the elderly. The rationale and study design
have been described previously.17 The medical ethics committee
of Erasmus University Medical School approved the study, and
written informed consent was obtained from each participant.Table 1. Descriptive Characteristics of Study Subjects by Cohort of Origin
Cohort (Country
of Origin) Diagnosis Criteria
Number in Discovery
Sample (Pooled GWAS)
Number in
Replication Studies
Number in
Meta-analysis
Age Years
(SD)
BMI kg/m2
(SD)
Chingford study (UK) Population-based,
radiographic knee OA
114 Fa OA, 196 F
controls
146 F OA, 243
F controls
260 F OA,
439 F controls
64.0 years
(SD ¼ 6.0)
26.7 kg/m2
(SD ¼ 4.6).
Case control (UK) Clinical knee OA
and age-matched
controls
243 F OA, 52 F
controls, 37 Ma
controls
258 F OA, 402
F controls
501 F OA,
454 F OA
73.0 years
(SD ¼ 8.5)
27.7 kg/m2
(SD ¼ 4.7)
TwinsUK (UK) Population-based,
radiographic knee OA
0 195 F OA, 885
F controls
165b F OA,
679b F controls
65.0 years
(SD ¼ 13.1)
25.1 kg/m2
(SD ¼ 4.4)
Case control (US) Clinical knee OA and
age-matched controls
0 272 F OA, 258
F controls
272 F OA,
258 F controls
60.5 years
(SD ¼ 8.9)
28.8 kg/m2
(SD ¼ 4.9)
Rotterdam study
(Netherlands)
Population-based,
radiographic knee OA
0 306 F OA, 584
F controls
306 F OA,
584 F controls
68.3 years
(SD ¼ 8.0)
26.7 kg/m2
(SD ¼ 4.1)
a F, female; M, male.
b Number of singletons.2008
The Chingford Study
The Chingford study is a prospective population-based longitudi-
nal cohort of womenwhowere derived from the age/sex register of
a large general practice in North London and who are representa-
tive of the general UK population in terms of weight, height, and
smoking characteristics.18 The study design and rationale are
described elsewhere in detail.19 The Guys and St Thomas’ Trust
and Waltham Forest Trust ethics committees approved the study
protocol. After study procedures were explained to participants,
they gave written consent.
TwinsUK
Participants were derived from the TwinsUK Adult Twin Registry
(Twin Research and Genetic Epidemiology Unit, St Thomas Hos-
pital, London, UK), a volunteer sample previously developed to
study the heritability and genetics of age-related diseases. These
twins, without selecting for particular diseases or traits, were
recruited from the general population through a series of national
media campaigns in the UK20 and were shown to be comparable
with age-matched population singletons in terms of disease-
related and lifestyle characteristics.21 The study was approved by
St Thomas’ Hospital Research Ethics Committee, and all twins
provided informed written consent.
Statistical Methods
Detection of Association from Pools
The difference in allele frequency between pools was expressed as
a Z score given by z ¼ jfcases  fcontrolsj/s where fcases is the esti-
mated frequency of a SNP allele in cases, fcontrols is the same in con-
trols, and s is a standard deviation given by both the sampling
error and the error owing to imprecise measurement of the allele
frequency in a pool as described in detail in 22.
False-Positive Report Probabilities
False-positive report probabilities were computed for the highest Z
scores coming out of the GWAS pooled analysis as described by
Wacholder et al.23 with the estimated allele frequencies from pools
to estimate odds ratios and conﬁdence intervals and the p value
corresponding to the Z scores.
Individual Polymorphism Genetic Associations
The association between individual SNP genotypes and OA was
tested by comparing SNP allele frequencies among cases and con-
trols with a Pearson’s chi-square test. Odds ratios with the corre-
sponding 95% conﬁdence intervals were also computed. Twins
in a pair are not independent and 255 twin pairs are part of the
samples from the TwinsUK cohort, to account for nonindepen-
dence; the family of origin was included as a random effect in
a mixed effects logistic regression model, with affected status
being the outcome variable.
Correction for Multiple Testing
The false discovery rate probability method (FDR)24 was used to
adjust formultiple testing for the replication genotypes carried out.
Fixed Effect Meta-analyses
To assess the overall evidence of association, we constructed
a Mantel-Haenszel meta-analysis of data from all cohorts. We
used theMantel-Haenszel chi-square test and theMantel-Haenszel
estimate of the odds ratio25 to provide a summary test and odds ra-
tio. Because twins in a pair are not independent for the TwinsUK
sample, the average value of both twins (both affected or both con-
trols) of the 255 twin pairs included was used, so that each of the
255 twin pairs counted as a single individuals for themeta-analysis
(Table 1).The AmLaboratory Methods
Pooled Genotyping
The pools compared consisted of 255 controls and 387 cases af-
fected with either radiographic or clinical OA of the knee (Table 1).
Genomic DNA samples were electrophoresed on 1.5% agarose
gels, and samples with intact genomic DNA showing no evidence
of contamination by RNA or of DNA degradation as revealed by
smearing on agarose-gel electrophoresis were selected for pooling.
Intact genomic DNA was diluted to 50 ng/ul concentration on
the basis of Quant-iT Picogreen (Invitrogen, Eugene, OR, USA)
quantitation, and then concentration was conﬁrmed by repeating
the picogreen analysis. Concentrations were adjusted on the basis
of these results, and picogreen analysis was repeated. This process
was repeated until all samples consistently measured 50 ng/ul.
We constructed pools by combining equal volumes of each DNA.
All pipetting steps were of volumes greater than 2ml forminimiza-
tionofpipetting error. Four replicates fromeachpoolwereprepared
and hybridized to the Illumina HumanHap550-Duo Genotyping
BeadChip microarray (Illumina, San Diego, CA, USA), according
to the manufacturer’s protocols. The Illumina genotype calling
algorithmwasmodiﬁed as previously described,22 in order tomax-
imize its accuracy in the context of pooled DNA genotyping.
Estimates of allele frequencies were obtained on the basis of the
hybridization intensities from the two probes corresponding to
eachSNPallele.Median signalwasdetermined for bothalleles for ge-
notypesAA,AB,andBBfor eachSNP,enablingus tocompute thecor-
responding relative allele signal, and this was then used to estimate
the allele frequency as has been described in detail previously.22
Approximately 64,000 SNPs were removed from the list for dif-
ferent reasons: low informativeness among individuals of Euro-
pean descent (MAF % 1%), high level of noise, which was deter-
mined by comparing allele frequency of the same SNP in the
same pool but using data from the different chips (SNPs with
a standard deviation of allele frequency above 10%), or because
they were in total LD with other SNPs in the list. For some SNPs,
when the allele frequency was measured on different chips,
some strong outliers were observed and such SNPs were excluded.
Because 37menwere part of the controls in the pools but nomales
were included in the cases, markers from the X chromosome were
not considered for analysis. The total number of markers analyzed
was therefore 413,461.
Individual Genotyping
All samples except those from the Rotterdam cohort were carried
out by Kbioscience, Hertfordshire, UK. SNPs were genotyped
with the KASPar chemistry, which is a competitive allele-speciﬁc
PCR SNP genotyping system using FRET quencher cassette oligos.
Genotyping accuracy, as determined from the genotype concor-
dance between duplicate samples, was 99.6%. The genotyping suc-
cess rate was 97.9%. All polymorphisms were in Hardy-Weinberg
equilibrium in controls (all p > 0.05). Genotyping in the Rotter-
dam cohort was performed with the Illumina HumanHap 550
SNP array.
Gene-Expression Studies
For gene-expression studies, articular chondrocytes were isolated
from femoral cartilage obtained from patients with osteoarthritis
undergoing knee-replacement surgery (one female aged 70 years
and four males, one aged 66, two aged 73, and one aged 89 years)
as described previously.26 RNA from freshly isolated chondrocytes
was obtained with QIAGEN RNAeasy (QIAGEN, Venlo, The Neth-
erlands) kit according to the manufacturer’s protocol. After reverse
transcription with a RevertAid H Minus complementary DNA
(cDNA) synthesis kit (Fermentas, St. Leon-Rot, Germany), cDNAerican Journal of Human Genetics 82, 1231–1240, June 2008 1233
templates were used for PCR. Primers were designed with Vector
NTI (Invitrogen, Carlsbad, CA, USA). The expression of the prosta-
glandin endoperoxide synthase 2 (PTGS2 [MIM 600262]) and the
phospholipase A2, group IVA (PLA2G4A [MIM 600522]) genes was
investigated. Primer sequences were PTGS2 sense primer 50-AAG
TCCCTGAGCATCTACGG-30, PTGS2 antisense primer 50-ATGCCA
GTGATAGAGGGTGTT-30, PLA2G4A sense primer 50-TTGCTGGT
CTTTCTGGCTC-30, and PLA2G4A antisense primer 50-TTCATCAT
CACTGTCCGAGC-30. Complementary DNA was mixed with 0.5
units of Taq polymerase (Eurogentec, Seraing, Belgium), 0.2 mM
dNTP, 0.5 M speciﬁc primers, and 1.5 mM MgCl2. For PTGS2
and PLA2G4A, annealing temperatures of 55C and 60C were
used, respectively. PCRs were run for 30 cycles and products
were visualized on 1.2% agarose gels.
Allelic Expression Analysis
By using a protocol described previously,27 we extracted nucleic
acid from articular cartilage of UKOA patients who had undergone
hip- or knee-replacement surgery (THR and TKR, respectively). The
cartilage genomic DNA was used to genotype the patients for SNP
rs5275, which is located in the 30 UTR of PTGS2, and for SNP
rs4140564, which is located 50 to PTGS2. Three THR (all females)
and three TKR (two females and onemale) patients were identiﬁed
as compound heterozygous for both SNPs, whereas one THR (fe-
male) and two TKR (one female and one male) patients were iden-
tiﬁed as heterozygous for SNP rs5275 but homozygous (TT) for
SNP rs4140564. The cartilage RNA from these nine patients was
then taken forward for an allelic expression analysis using a single
base extension (SBE) assay that we have described in detail previ-
ously.28 At least 240 ng of RNA was used for the cDNA synthesis
with random hexamers and the SuperScript kit (Invitrogen, Pais-
ley, UK). Two reverse transcription (RT) reactions were performed
for each patient: with (þRT) and without (RT) reverse transcrip-
tase. From each þRT reaction,R19 individual PCR ampliﬁcations
were carried out with forward primer 50-ACTGTCGATGTTTC
CAATGC-30 and reverse primer 50-CAAACAAGCTTTTACAGGT
G-30, both located in the 30 UTR of PTGS2. The (RT) controls
did not yield detectable PCR products. The primer 50-CTAATGTTT
GAAATTTTAAAGTACTTTTGGT-30, which is located immediately
adjacent to SNP rs5275, was used for the SBE assay. To ascertain
the peak pattern for an assumed 1:1 ratio between alleles, we
performed ﬁve individual PCR and SBE reactions on the cartilage
genomic DNA of each of the nine patients to yield a total of 45 in-
dividual genomic DNAmeasurements. The same PCR primers and
SBE primer were used for the cDNA and genomic template. By em-
ploying the same analytic conditions for the cDNA and genomic
DNA measurements, we were able to use the average of the 45 ge-
nomic DNA allelic ratio measurements (representing the assumed
1:1 ratio between alleles) to correct the allelic ratios obtained from
the cDNA measurements and thus to account for differences in
ﬂuorescent yield and terminator-dye incorporation speciﬁc to
the assay. Such correction allowed us to obtain exact values of
the relative allelic expression of each cDNA measurement. To
determine whether there was a signiﬁcant difference in allelic ex-
pression for each patient, we compared the cDNA allelic ratios for
that patient to the pooled genomic allelic ratios by using a
two-tailed Mann-Whitney exact test.
Results
None of the SNPs tested in the pooled genome-wide scan
achieved p values that could be considered as genome-1234 The American Journal of Human Genetics 82, 1231–1240, Junwide signiﬁcant with a Bonferroni correction for multiple
tests i.e., log10p ¼ 6.92 (not shown). We thus selected
the genetic variants with a high likelihood of being truly
associated with disease by using the false-positive rate
probability method (FPRP) developed by Wacholder
et al.23 In total, 28 SNPs resulted from this GWAS that
had FPRP % 0.5 (Table 2). These SNPs were individually
genotyped in the samples used for the pools and also in
an additional 1530 controls and 599 cases from the UK
and 272 cases and 258 controls from the U.S. as shown
in Figure 1. The 37 male controls in the pools were also
individually genotyped, and allele frequencies were found
to be the same as in female controls. However, for consis-
tency we did not include data from male samples in any
of the subsequent analyses (Table 1).
The 28 SNPs had an average minor allele frequency
(MAF) of 13%. Both replication cohorts combined had
80% power to detect as statistically signiﬁcant odds ratios
of 1.39 with p < 0.0017 (Bonferroni a ¼ 0.05 for 28 tests)
for MAFs of 13%.
From the individual genotyping of 28 SNPs, we esti-
mated that the genotyping error in pools was 3.1% (SE 5
0.5%), although this estimate cannot be extrapolated to
other markers in the pooled GWAS because SNPs with
high Z scores had signiﬁcantly lower errors due to impre-
cise measurement of the allele frequency in a pool than
nonsigniﬁcant SNPs (not shown). Combining the test
and replication samples, we found that 14 out of the 28
SNPs were nominally statistically signiﬁcant (p < 0.05);
this is consistent with the prior probability of 0.0005
used for the FPRP calculation. However, only one SNP
rs4140564 was associated in both the U.S. and UK replica-
tion cohorts after adjusting for multiple testing (Table 3).
We selected the seven markers with the smallest overall
nominal p values (p < 0.002), and these were then tested
for association in a population-based cohort from theNeth-
erlands. Table 4 shows the odds ratios in the Rotterdam
cohort for these variants as well as the overall Mantel-
Haenszel odds ratio combining all samples, including those
used for the GWAS. In addition, a Mantel-Haenszel odds
ratio combining all replication samples, excluding those
from the pools, is shown.
Only rs4140564 was nominally signiﬁcantly associated
in the Rotterdam cohort with an odds ratio of 1.56 (p <
0.026, Table 3). The summary Mantel-Haenszel odds ratio
over all samples was ORMH ¼ 1.55 (nominal p < 7 3
107) (Table 4). The association of rs4140564 with knee
OA in the three replication cohorts, excluding the samples
that had been used for the pooled GWAS, was also statisti-
cally signiﬁcant with p < 5.6 3 106 (Table 4). Because the
UK samples used for the GWAS and for replication are de-
rived from three independent studies, we also estimated
the odds ratio in each of this individual UK cohorts and
found an OR ¼ 1.54 (95% CI 1.05–2.27) for the UK case-
control samples, OR ¼ 1.54 (95% CI 1.03–2.31) for the
Chingford samples, and OR ¼ 1.56 (95% CI 1.04–2.34)
for the TwinsUK samples.e 2008
Table 2. SNPs from Pooled GWAS Selected to be Tested in Additional Samples
SNP Odds Ratio 95% C.I. Z Score log10 P
FPRP with
p ¼ 0.0005 Chr Position Nearest Gene(s)
rs4140564 3.34 1.89 5.92 4.312 5.09 0.124 1 184991626 PLA2G4A/PTGS2
rs1539414 1.67 1.19 2.33 4.170 4.82 0.288 1 194475163 DENND1B
rs12041748 2.39 1.59 3.59 4.654 5.79 0.104 1 235550588 RYR2
rs7581129 0.41 0.25 0.66 4.167 4.81 0.498 2 4160033 TSSC1
rs1207421 2.86 1.63 5.02 4.168 4.81 0.460 2 205976100 PARD3B
rs749052 0.28 0.17 0.46 4.305 5.08 0.004 2 232622115 NPPC
rs4955917 1.58 1.25 1.99 4.017 4.53 0.316 3 55021142 CACNA2D3/WNT5A
rs7628387 1.98 1.30 2.78 3.745 4.05 0.227 3 178046256 TBL1XR1
rs1961397 0.50 0.35 0.72 4.352 5.17 0.416 3 189111629 BCL6
rs1990525 3.76 1.93 7.29 4.282 5.03 0.287 4 15097292 C1QTNF7
rs7774801 5.28 2.60 10.89 4.048 4.59 0.029 6 22248420 PRL
rs1324089 2.37 1.49 3.78 4.095 4.68 0.089 6 85022001 C6orf84
rs7757372 1.83 1.18 2.83 4.094 4.67 0.203 6 143972097 PHACTR2
rs2057999 1.81 1.31 2.48 3.986 4.47 0.501 7 21147012 SP4
rs7005969 2.70 1.81 4.04 4.169 4.82 0.213 8 2926103 CSMD1
rs10504460 3.53 2.06 6.05 4.738 5.97 0.018 8 70886578 SLCO5A1
rs2453998 3.85 2.11 7.05 4.826 6.16 0.282 8 104158794 ATP6V1C1
rs2274699 2.47 1.61 3.79 4.182 4.84 0.114 9 71579586 TMEM2
rs7026263 1.77 1.20 2.63 4.114 4.71 0.099 9 133711962 VAV2
rs10823602 3.40 2.02 5.71 4.348 5.16 0.310 10 72145774 ADAMTS14
rs4531428 2.44 1.66 3.60 3.908 4.33 0.028 11 100917249 TRPC6
rs975162 0.50 0.36 0.68 4.785 6.07 0.039 12 125567785 PGBD3P3
rs3818287 1.94 1.35 2.78 4.196 4.87 0.203 14 102500300 CDC42BPB
rs751837 0.42 0.26 0.67 3.913 4.34 0.496 14 102554578 CDC42BPB
rs2896463 0.31 0.18 0.56 4.52 5.51 0.233 14 102560645 CDC42BPB
rs333603 0.69 0.53 0.84 4.008 4.51 0.415 15 64126454 MEGF11
rs7172123 2.59 1.64 4.09 4.552 5.58 0.389 15 66813101 CORO2B
rs6096822 2.83 1.73 4.61 3.957 4.42 0.433 20 35970860 C20orf102Of the other six SNPs, after excluding the samples in the
pools only rs1207421 and rs7628387 remained statistically
signiﬁcant overall (Table 4).
rs4140564 maps to a region in chromosome 1q25 that
falls 50 of both the PTGS2 and the PLA2G4A genes, which
encode the cyclooxygenase 2 (COX-2) and the cytosolic
phospholipase A2 enzymes, respectively. To assess whether
PTGS2 and PLA2G4A were expressed in cartilage, we con-
ducted an RT-PCR analysis for both genes on freshly iso-
lated chondrocytes from knee OA cartilage. Both genes
were abundantly expressed in all patients tested (Figure 2).
On the other hand, expression of PTGS2 was minimal
in placenta and normal synovium, and expression of
PLA2G4A was minimal in placenta and was absent in
normal synovium.
Analysis of the LD block (r2R 0.8) for individuals of Eu-
ropean descent in the Perlegen Genome Browser (build
36) indicated that rs4140564 tags variation covering the
whole of the PTGS2 gene, including its 30 and 50 untrans-
lated regions SNP (Figure 3), but not the PLA2G4A gene.
Because rs4140564 is tagging PTGS2 but only a distant
50 region of PLA2G4A gene, we hypothesized that this var-
iant, or a variant in LD with it, may affect the expression
of PTGS2. To assess whether this was the case, we identi-
ﬁed six OA patients (patients 1–6 in Figure 4) who had un-
dergone joint replacement of a hip or of a knee and who
were heterozygous both at SNP rs4140564 and at another
SNP (rs5275). This second SNP was selected because, un-The Amlike rs4140564, it is part of the PTGS2 RNA transcript (Fig-
ure 3). rs5275 is located in the 30 UTR of PTGS2 and thus
enabled us to directly measure allelic expression at PTGS2
by comparing the mRNA allelic ratios of heterozygotes
and DNA ratios. For an autosomal locus, DNA ratios for
a heterozygote should always be 1.0, but if one of the
alleles is in LD with a SNP that affects transcription or
mRNA stability, the RNA ratios will be different from
1.0. Two of the six double-heterozygote individuals (pa-
tients 3 and 5 in Figure 4) demonstrated highly signiﬁcant
differences in allelic expression (p < 1.0 3 106). Patient 3
was a male who had undergone a knee replacement at 76
years of age, whereas patient 5 was a female who had
undergone a hip replacement at 65 years of age. SNPs
rs4140564 and rs5275 have different minor-allele fre-
quencies and are not in complete LD (pair-wise r2 ¼
0.14) as seen by the haplotype frequencies in UK samples
shown in Figure 4. However, we can conclude that for pa-
tients 3 and 5, marker rs4140564 is linked to a regulatory
variant of PTGS2 whose alleles mediate different levels of
PTGS2 expression.
We also investigated three OA patients (patients 7–
9 in Figure 4) who were heterozygous at rs5275 but
homozygous (TT) for the marker associated with OA
rs4140564. One of these patients (patient 9, a male who
had undergone a knee replacement at age 68) demon-
strated signiﬁcant differences in allelic expression (p <
0.005).erican Journal of Human Genetics 82, 1231–1240, June 2008 1235
Table 3. Association of 28 Markers with Knee OA in Two Replication Sets
SNP ID
MAF %
Controls/OA OR UK (95% CI)
p Value
Nominal
p Value
FDR OR US (95% CI)
p Value
nominal
p Value
FDR
Discovery þ
Replication
ORMH (95% CI)
p Value
Nominal
rs4140564a 5.4/8.4 1.44 (1.11–1.87) 0.0056 0.0391 1.77 (1.21–2.57) 0.0026 0.0242 1.59 (1.31–1.94) 3 3 106
rs1539414 21.8/22.5 1.04 (0.89–1.23) n.s. n.s. 0.81 (0.61–1.09) n.s. n.s. 1.06 (0.94–1.21) n.s.
rs12041748 12.7/14.6 1.02 (0.84–1.24) n.s. n.s. 1.16 (0.88–1.54) n.s. n.s. 1.17 (1.01–1.35) 0.04
rs7581129 6.3/6.7 0.92 (0.7–1.22) n.s. n.s. 2.30 (1.40–3.77) 0.0007 0.0105 0.99 (0.79–1.25) n.s.
rs1207421 9.3/12.8 1.40 (1.14–1.72) 0.0012 0.0163 1.04 (0.69–1.57) n.s. n.s. 1.46 (1.24–1.73) 6 3 106
rs749052 7.2/7.0 1.11 (0.85–1.44) n.s. n.s. 1.20 (0.76–1.89) n.s. n.s. 0.93 (0.75–1.15) n.s.
rs4955917 26.1 /27.6 1.06 (0.92–1.23) n.s. n.s. 0.85 (0.61–1.17) n.s. n.s. 1.05 (0.95–1.24) n.s.
rs7628387 12.6/16.0 1.26 (1.05–1.52) 0.0154 0.0862 1.29 (0.90–1.83) n.s. n.s. 1.30 (1.12–1.51) 0.0007
rs1961397 10.7/10.1 0.98 (0.78–1.23) n.s. n.s. 1.02 (0.69–1.52) n.s. n.s. 0.91 (0.76–1.08) n.s.
rs1990525 7.5/7.5 0.90 (0.7–1.16) n.s. n.s. 0.64 (0.40–1.05) 0.0755 n.s. 1.04 (0.85–1.28) n.s.
rs7774801 9.5/12.7 1.18 (0.95–1.47) n.s. n.s. 1.34 (1.00–1.80) 0.0533 n.s. 1.38 (1.18–1.62) 6 3 105
rs1324089 22.1/23.6 1.01 (0.85–1.18) n.s. n.s. 0.98 (0.74–1.30) n.s. n.s. 1.11 (0.98–1.26) 0.09
rs7757372 22.7/26.6 1.13 (0.97–1.31) n.s. n.s. 1.09 (0.82–1.44) n.s. n.s. 1.24 (1.09–1.40) 0.0007
rs2057999 16.5/19.1 1.13 (0.95–1.35) n.s. n.s. 1.40 (1.02–1.91) 0.0343 n.s. 1.21 (1.05–1.39) 0.006
rs7005969 17.7/18.3 0.89 (0.75–1.05) n.s. n.s. 0.89 (0.64–1.24) n.s. n.s. 1.05 (0.91–1.20) n.s.
rs10504460 8.4/10.1 1.05 (0.84–1.32) n.s. n.s. 0.96 (0.58, 1.51) n.s. n.s. 1.19 (1.00–1.51) 0.050
rs2453998 4.9/5.1 0.89 (0.65–1.22) n.s. n.s. 1.00 (0.61–1.64) n.s. n.s. 1.05 (0.81–1.36) n.s.
rs2274699 8.0/8.8 1.04 (0.83–1.31) n.s. n.s. 0.71 (0.43–1.17) n.s. n.s. 1.11 (0.92–1.34) n.s.
rs7026263 15.4/16.7 1.02 (0.85–1.22) n.s. n.s 1.08 (0.77–1.51) n.s. n.s. 1.11 (0.96–1.28) n.s.
rs10823602 9.7/11.6 0.93 (0.74–1.17) n.s. n.s. 1.18 (0.83–1.69) 0.0272 n.s. 1.2 (1.02–1.41) 0.025
rs4531428 18.6/22.0 1.11 (0.94–1.31) n.s. n.s. 1.37 (1.02–1.85) 0.0388 n.s. 1.22 (1.07–1.40) 0.003
rs975162 14.2/12.1 0.99 (0.81–1.21) n.s. n.s 0.68 (0.50–0.93) 0.0145 0.1014 0.82 (0.70–0.95) 0.009
rs3818287 14.7/15.8 0.99 (0.83–1.19) n.s. n.s. 1.09 (0.78–1.54) n.s. n.s. 1.09 (0.94–1.27) n.s.
rs751837 11.6/9.8 0.67 (0.53–0.84) 0.0007 0.0188 1.43 (0.98–2.08) 0.0601 n.s. 0.76 (0.63–0.90) 0.0015
rs2896463 8.7/7.1 0.68 (0.52–0.89) 0.0046 0.0432 1.33 (0.87–2.05) n.s. n.s. 0.74 (0.60–0.91) 0.003
rs333603 24.8/24.8 0.83 (0.71–0.98) 0.0238 0.0953 1.69 (1.28–2.22) 0.0002 0.0046 0.95 (0.84–1.08) n.s.
rs7172123 9.0/12.2 1.31 (1.04–1.64) 0.0204 0.0954 1.34 (1.01–1.77) 0.0400 n.s. 1.37 (1.16–1.62) 0.0001
rs6096822 7.2/8.3 1.01 (0.78–1.29) n.s. n.s. 1.27 (0.92–1.77) n.s. n.s. 1.17 (0.97–1.41) 0.10
Odds ratios and 95% confidence intervals are shown for each replication study along with the nominal and false discovery rate (FDR) adjusted p values
(if %0.10). The summary Mantel-Haenszel odds ratio for all samples (discovery plus replication combined) is shown. Minor allele frequencies (MAF)
are averaged over the U.S. and UK control and case samples.
a SNPs with nominal overall p values < 0.002 are highlighted in bold.Discussion
By using a pooled genome-wide scan approach and subse-
quently testing these variants in independent cohorts, we
uncovered seven SNPs associated with knee OA but only
one that is associated in the ﬁve cohorts studied. Two of
those seven SNPs, rs7628387 and rs1207421 were overall
signiﬁcantly associated when samples used for the GWAS1236 The American Journal of Human Genetics 82, 1231–1240, Junwere excluded. rs1207421 maps to chromosome 2q33,
not far from a previously reported linkage peak for hip
OA at 2q31.1.4 Moreover, this SNP maps in the middle of
a genome-wide linkage peak of extended early-onset OA
families,29 making it likely that the genomic region near
this marker harbors as-yet-unknown OA-susceptibility
genes. rs7628387 on the other hand, maps to 3q26, which
is not near any known linkage peak.Table 4. Association of Seven Markers in the Rotterdam Cohort and Meta-analysis in All Study Samples and in Replication
Samples Only
SNP ID
O.R. and Nominal p
Value in
Rotterdam Study ORMH All 95% CI
Nominal p Value,
All Samples
ORMH Replication
Samples Onlya 95% CI
Nominal p
Value Replication,
Samples Onlya
rs4140564 1.56 (1.05–2.32), p < 0.026 1.55 (1.30–1.85) 6.9 3 107 1.54 (1.28–1.86) 5.6 3 106
rs1207421 1.14 (0.81–1.61), n.s. 1.40 (1.20– 1.62) 1.2 3 105 1.28 (1.09– 1.50) 0.0028
rs7628387 1.02 (0.64–1.27), n.s. 1.23 (1.08–1.41) 0.0022 1.19 (1.03–1.38) 0.014
rs7774801 0.90 (0.64–1.27), n.s. 1.28 (1.10–1.48) 8.0 3 104 1.15 (0.98–1.34) 0.073
rs7757372 1.03 (0.82–1.30), n.s. 1.19 (1.07–1.32) 0.0019 1.10 (0.98–1.23) n.s.
rs751837 1.06 (0.76–1.49), n.s. 0.81 (0.69–0.95) 0.0072 0.87 (0.74–1.04) n.s.
rs7172123 0.76 (0.54–1.07), n.s. 1.22 (1.05–1.42) 0.0070 1.13 (0.99–1.29) 0.077
a With data from the UK, U.S., and Rotterdam replication cohorts and excluding all samples used for the pooled GWAS.e 2008
The effect sizes derived from the GWAS on a small subset
were all overestimated. This pattern can be explained by
the so-called ‘‘winner’s curse,’’ which has been already dis-
cussed by other authors,30 but we note that the odds ratios
for predisposing variants in the original GWASwere greater
than 1.5 and as high as 5.6, whereas the actual ORs in the
combined test plus replication samples were <1.6, consis-
tent with other genetic associations with knee OA reported
to date.
The pooled genome-wide scan presented here was un-
derpowered as shown by the fact that no single variant
achieved genome-wide signiﬁcance. A true odds ratio of
2.4 or greater would have been required to achieve 80%
power with a ¼ 1.2 3 107 in the discovery sample size
studied given a MAF that equaled 13% (average for the
SNPs in Tables 2 and 3). Nevertheless, the approach uti-
lized illustrates the value of using a pooled GWAS followed
by the exclusion of markers that have a high probability of
being false positives to uncover variants associated with
disease. Several studies showing the validity of pooled
Figure 2. Expression of PLA2G4A and PTGS2 in Chondrocytes
PTGS2 and PLA2G4A gene expression was tested by RT-PCR on
mRNA obtained from freshly isolated knee-cartilage chondrocytes
from five OA patients. The primers amplified a 330 bp PTGS2 PCR
product and a 650 bp PLA2G4A PCR product. Human placenta and
normal synovium were used as noncartilage control tissues.
Water was used as negative control.GWAS for complex traits have recently been published,
and this approach is considered by some authors as a valid
cost-effective method for discovering associations of vari-
ants with disease.31
The polymorphism that is associated with OA in all sam-
ples studied, rs4140564, is located 50 to PTGS2, and we hy-
pothesized that it may be a regulatory polymorphism for
this gene or that it may be in linkage disequilibrium (LD)
with a regulatory polymorphism. Our allelic expression
studies using RNA extracted from the cartilage of OA
patients supports the existence of cis-acting polymor-
phisms that can modulate the expression of PTGS2. Not
all six of the compound-heterozygote patients that
we studied however demonstrated differential allelic ex-
pression, suggesting that rs4140564 is unlikely to be the
regulatory polymorphism itself, but rather it is likely to
be in modest LD with a marker-affecting expression. This
is further supported by our observation that a patient
who was homozygous at rs4140564 also demonstrated dif-
ferential allelic expression. Identifying the functional reg-
ulatory polymorphism will require a comprehensive anal-
ysis of other variants within and close to PTGS2 to see
which show the strongest correlation with differential alle-
lic expression. This search may be expedited by an analysis
of evolutionarily conserved sequences.
The two genes ﬂanking rs4140564, PTGS2 and PLA2G4A,
not only map nearby in the genome but are also both part
of the prostaglandin E2 synthesis pathway. Prostaglandin
E2 (PGE2) mediates the regulation of important biological
processes such as proliferation and differentiation of artic-
ular chondrocytes in both normal and pathological
states.32 The production of PGE2 involves a cascade of
three enzyme reactions. First, arachidonic acid is liberated
from its phospholipid storage sites by a phospholipase A2
(PLA2); it is then acted on by cyclooxygenases and ﬁnally
by PGE synthase to produce PGE2.33
The COX-2 protein is the product of the PTGS2 gene in
humans and has been reported to be expressed in OA me-
niscus, synovial membrane, and osteophytic ﬁbrocartilage
explants and at lower levels in OA articular cartilage, inFigure 3. Position on Chromosome 1 of the PTGS2 and PLA2G4A Genes, rs4140564 and rs5275 SNPs
The LD block for rs4140564 (from Perlegen Genome browser build36) is shown, as are the frequencies of rs5275-rs4140564 haplotypes in
UK samples.
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particular during early OA.34 Our expression-analysis study
conﬁrms that the transcripts of two genes related to the
synthesis of PGE2 are abundantly expressed in chondro-
cytes from OA patients.
Although OA is known to be a noninﬂammatory pathol-
ogy, there is a growing body of evidence indicating that
there is a signiﬁcant inﬂammatory component to disease
pathogenesis.35,36 Strong associations between PTGS2 vari-
ants and radiographic features of OA of the spine have been
previously reported,37 and the results from the present
study indicate that genetic variation near PTGS2 is impor-
tant also for other formsofOA.Multiple reportshave shown
that PGE2 is involved in the pathogenesis of OA.38,39 In-
creased COX-2 expression has been reported in cartilage
and synovial tissues from patients with OA and also in sev-
eral models of cartilage degradation.39,40 However, the role
of COX-2 in OA is still controversial. Animal studies have
shown that during the early phase of inﬂammation, COX-2
is clearlyproinﬂammatory, but during the later phases of in-
ﬂammation dominated by mononuclear cells, COX-2 ap-
pears to have anti-inﬂammatory effects by generating an al-
ternate set of anti-inﬂammatory prostaglandins.41 Further,
whereas some ﬁndings suggest that PGE2 mediates the in-
terleukin 1 beta (IL-1b) effect on cartilage degradation,42
PGE2may also have positive effects on cartilage by increas-
ing the level of glucocorticoid receptors in chondrocyte
cells, inﬂuencing cartilagedifferentiation andproliferation,
andmediating the effects of vitaminD on cartilage.43,44 Re-
cent in vitro studies in human chondrocytes provide evi-
dence that both tumor necrosis alpha (TNF-a) and IL-1b dif-
ferentially regulate the activation of the apoptotic pathway
Figure 4. Allelic Expression Analysis at PTGS2 SNP rs5275
Expression analysis was carried out for nine UK patients who had
severe end-stage OA with RNA extracted from articular cartilage.
For each patient, 19 (patient 1) or 20 (patients 2–9) individual
cDNA amplifications and SBE reactions were performed. Forty-five
individual PCR and SBE reactions were performed for genomic
DNA (five reactions per patient). The cDNA allelic ratios were com-
pared with the 45 genomic ratios with a two-tailed Mann-Whitney
exact test. Four patients had undergone a THR (H), and five
patients had undergone TKR (K). Data shown are the mean þSD,
*p < 0.005; ***p < 1.0 3 106.1238 The American Journal of Human Genetics 82, 1231–1240, Junein human chondrocyte cells but that PGE2 does not modu-
late apoptosis.45 Other studies reported that TNF-a-medi-
ated protection of chondrocytes from nitric-oxide-induced
apoptosis requires COX-2 activity.44
Given the complex and multiple pathways of regulatory
stimuli affecting COX-2 expression, and the discrepant
effects that can be observed in vitro, genetic variants that
result in either higher or lower expression of COX-2 in re-
sponse to proinﬂammatory cytokines or nitric oxide have
the potential of resulting in higher risk of OA. This would
depend on how transcriptional regulation of the PTGS2
gene by cytokines and nitric oxide is inﬂuenced, on how
regulatory loops of the COX enzymes are inﬂuenced, and
on the stage during the pathogenesis of OA at which the
differential response to transcriptional regulatory factors
takes place. The data found in our study suggest that an
allele in LD with the risk-associated allele at rs4140564 is
involved in lower expression of mRNA encoding COX-2.
More elaborate experiments are needed to understand
the precise mechanism by which rs4140564 or other vari-
ants in LD with it are inﬂuencing risk of OA.
The expression differences that we observed between
PTGS2 alleles in patients 3, 5, and 9 were relatively small,
ranging from8%–18%.However, these differences are com-
parable to those observed for the recently reportedOA-asso-
ciated functional SNP rs143383, which is located in the 50
UTR of the growth/differentiation factor 5 (GDF5 [MIM
601146]),26 a gene which has been shown to affect risk of
hip and knee OA in both Asian and European individuals.6
However, because only two of the six rs4140564 heterozy-
gote patients showed decreased PTGS2 expression, and
given the controversial role of COX-2 inOA, we canmerely
hypothesize that the mechanism involved in increased OA
risk could be through differential modulation of PTGS2
expression. Other possible explanations, which we did
not explore, are that rs4140564 or a polymorphism in LD
with it might be affecting expression of PLA2G4A or that
rs4140564might be in LD with variants affecting the func-
tionof either the PLA2G4A or PTGS2or both geneproducts.
In conclusion, our data indicate that a polymorphism in
LD with variants affecting the expression of the PTGS2
gene are associated with susceptibility to knee OA in ﬁve
independent populations and highlight the importance
of inﬂammatory pathways in OA pathogenesis.
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